

# Neuroprotective effects of ginsenosides

# Wolf-Dieter Rausch<sup>1</sup>, Shu Liu<sup>2</sup>, Gabriele Gille<sup>3</sup>, and Khaled Radad<sup>4</sup>

<sup>1</sup>Institute for Medical Chemistry, Veterinary Medical University, Veterinärplatz ,1 A-1210 Vienna, Austria; <sup>2</sup>Institute of Beijing Geriatric Clinic and Research Centre, Xuanwu Hospital, Capital University of Medical Science, Beijing 100053, China; <sup>3</sup>Department of Neurology, Technical University, Fetscherstr. 74, 01307 Dresden, Germany; <sup>4</sup>Department of Pathology, Faculty of Veterinary Medicine, Assiut University, Egypt



**Abstract.** Ginseng, the root of the *Panax* species, is a well-known herbal medicine. Traditionally it has been used in Korea, China and Japan for thousands of years. Nowadays it has become a popular and worldwide known health drug. Current scientific studies demonstrate in vivo and in vitro its beneficial effects in a wide range of pathological conditions such as cardiovascular disease, cancer, immune deficiency and hepatotoxicity. Ginsenosides or ginseng saponins as the active ingredients have antioxidant, anti-inflammatory, anti-apoptotic and immunostimulant properties, which raised speculations that these compounds could positively affect neurodegenerative disorders and delay neuronal aging. Conclusive clinical data in humans are still missing. However, results from animal studies and neuronal cell culture experiments indicate that ginsenosides can counteract and attenuate factors promoting neuronal death as environmental toxins, excitotoxic action of glutamate and rises in intracellular calcium, excessive release of free radicals and apoptotic events. Thus, neuroprotective actions of ginsenosides could come about as a valuable option to slow down neurodegenerative diseases.

Correspondence should be addressed to W.D. Rausch, Email: wolf.rausch@vu-wien.ac.at

Key words: ginsenosides, neurodegeneration, antioxidative, neuroprotection

### INTRODUCTION

## The concept of neuroprotection

The term neuroprotection refers to measures antagonizing and delaying neuronal loss by slowing or blocking processes, which cause death of nerve cells either prematurely or in old age (Gerlach et al. 2000). Generally it refers to phenomena which are antagonizing oxidative stress in nervous tissue. Oxidative stress is defined as the general principle of an imbalance in between the formation and the detoxification of reactive oxygen species in favor of the former. These reactive oxygen species include hydrogen peroxide and such oxygen derived radicals as the hydroxy radical, the superoxide radical and NO. When not sufficiently scavenged, these small molecules may cause DNAdeletions and mutations, lipid peroxidation causing membrane damage, and alterations in proteins are generated.

Radical detoxification processes either involve enzymatic action of superoxide dismutase, glutathione peroxidase and catalase as well as such water soluble antioxidants as ascorbic acid, GSH and cysteine as well as lipid soluble molecules such as tocopherols, coenzyme Q and carotinoids.

Neuroprotective properties have been attributed to a constantly growing number of compounds as receptor agonists (e.g., dopamine agonists – Radad et al. 2005)

or a range of such natural compounds as flavonoids or natural medicines (e.g., ginseng, Liu et al. 2006).

### Ginsenosides, the active ingredients of ginseng root

Ginseng refers to the roots of several species in the plant genus *Panax* (C.A. Meyer *Araliaceae*). Among them, Panax ginseng is the most widely used being indigenous to Far East countries (most notably Korea and China). Panax ginseng has a medical history of more than five thousand years. The genus name of Panax ginseng "Panax" was given by the Russian botanist C.A. Meyer, and is derived from the Greek words "pan" meaning all and "axos" meaning cure. The species name "ginseng" comes from the Chinese word "rensheng" which means "human" as ginseng roots resemble the human body (Noverino et al. 2000).

Ginsenosides or ginseng saponins represent the principle active ingredients in ginseng and more than thirty different analogues have been identified (Yun 2001). They consist of a gonane steroid nucleus with 17 carbon atoms arranged in four rings. The characteristic biological responses for each ginsenoside are attributed to the differences in the type, position and number of sugar moieties attached by glycosidic bond at C-3 and C-6 (Fig. 1). Based on their structural differences, they can be classified into three categories: the panaxadiol group (e.g. Rb1, Rb2, Rb3, Rc, Rd,




Fig. 1. Chemical structures of both ginsenosides Rb1 and Rg1. Ginsenoside Rb1 is an example for 20(S)-protopanaxadiol type while Rg1 for 20(S)-protopanaxatriol type.

Rg3, Rh2, Rs1), the panaxatriol group (e.g. Re, Rf, Rg1, Rg2, Rh1), and the oleanolic acid group (e.g., Ro) (Wen et al. 1996).

#### General effects attributed to ginseng

Ginseng products are commonly used as general tonic and adaptogen to help the body to resist the adverse influences of a wide range of physical, chemical and biological factors and to restore homeostasis (Blumenthal 2001). These tonic and adaptogenic effects of ginseng are believed to enhance physical performance including sexual function and general vitality in healthy individuals, to increase the body's ability to fight stress in stressful circumstances and to support resistance to diseases by strengthening normal body function as well as to reduce the detrimental effects of the aging processes (Tyler 1993). Current reviews on pharmacological and biological activities on ginsenosides are recommended for reference (Zhang 2006).

# Effects of ginsenosides on cognitive function and decline

The use of herbal medicine, particularly ginseng, for improving cognitive performance has become increasingly popular during recent years and some studies have shown its enhancing effects on learning and memory either in aged and/or brain damaged individuals (Yamaguchi et al. 1996). For example, significant improvement in learning and memory has been observed in aged and brain-damaged rats after local administration of ginseng powder (Kennedy and Scholey 2003). In humans, Terasawa and coauthors (1997) have shown that ginseng or ginseng extract had significant effects on neurological and psychiatric symptoms in aged humans and psychomotor functions in healthy subjects respectively. This positive effect of ginseng on cognition derives from the direct action of ginseng on the hippocampus. Moreover, Shen and Zhang (2003) suggested that the influence of ginsenoside Rg1 on the proliferating ability of neuronal progenitor cells may serve as an important mechanism underlying its nootropic and anti-aging effects particularly on learning and memory. This still appears controversial, as in healthy individuals the regular use of ginseng during long time periods (up to 2 years) did not provide quantifiable beneficial effects on memory performance (Persson et al. 2004).

#### Ginseng rescues neuronal cells in vivo

It has been shown that ginseng and its saponins have a wide range of actions in the central nervous system. These effects include increased neural survival, extension of neurite growth and rescuing of neurons from death due to different insults and deficient supply either in vivo or in vitro, e.g., in ischemia in gerbils central infusion of ginsenoside Rb1 rescued hippocampal neurons from cellular hypoxia (Lim et al. 1997, Wen et al. 1996).

# Ginsenoside effects on pesticides and other environmental toxicants

Due to their presence in the environment and the direct exposure of humans and animals neurotoxic actions for a wide range of pesticides are currently of concern. Though accumulation and long term-low dose toxicity are far from being understood, the action of pesticides as rotenone, polychlorinated biphenyls (PCBs) and fungal toxins can be demonstrated in neuronal cell cultures, where the impact is directed against mitochondrial function or also involves specific receptor action. Interestingly ginsenosides appear to attenuate these effects.

Rotenone as a common household pesticide is a specific and irreversible inhibitor of complex I of the mitochondrial chain (Antkiewicz-Michaluk et al. 2003, Betarbet et al. 2000). Ginsenoside Rg1 showed neuroprotective action, presumably by interacting with glucocorticoid receptors as their receptor antagonists prevented this effect. (Leung et al. 2006). 3-Nitropropionic acid is a compound found in crops contaminated with fungi and causes neurotoxicity both in humans and animals. As the compound induces a selective striatal pathology, it has been widely used as an agent to model Huntington's disease. Against striatal infusion as well as in striatal neuronal cultures ginseng saponins exerted neuroprotective action, which was found as a reversion of Ca2+-increases and a normalisation of mitochondrial depolarisation (Kim et al. 2006). PCBs as environmental pollutants are highly persistent in nature and some congeners as PCB-52 exert neurotoxic action. Including ginsenosides in the medium reduced lipid peroxidation, apoptotic events and DNA fragmentation caused by this congener (Moon et al. 2006).

#### Ginsenoside effects in Parkinson's disease models

Agents such as 1-methyl-4-phenyl-1,2,3,6-tetrahy-dropyridine (MPTP) can cause parkinsonian features in man and experimental animals. Prolonged oral administration of ginseng extract G115 significantly prevented neurotoxic effects of MPTP in rodents (Van Kampen et al. 2003). 1-Methyl-4-phenylpyridinium (MPP+), the active metabolite of MPTP is selectively toxic to dopaminergic neurons in culture. The degenerative changes by MPP+ as e.g., a loss of dendritic processes is effectively reduced by ginsenoside Rb1 (Radad et al. 2004a).

In order to elucidate the neuroprotective mechanism of ginseng for dopaminergic neurons, several reports demonstrate the inhibitory role of ginseng on MPP<sup>+</sup> uptake in dopaminergic neurons, the suppression of oxidative stress induced by autooxidation of dopamine, the attenuation of MPP<sup>+</sup>-induced apoptosis and the potentiation of nerve growth factor action. Ginsenosides inhibited dopamine uptake into rat synaptosomes (Tsang et al. 1985) and consequently ginseng could provide protection against MPP<sup>+</sup> through blockade of its uptake into dopaminergic neurons. Ginsenoside Rg1 may interrupt dopamine-induced elevation of reactive oxygen species or nitric oxide generation in pheochromocytoma cells (Chun et al. 2003).

# Glutamate as an excitotoxin may contribute to neuronal death

Excitotoxic events could be important triggers for cell death in the nervous system. Glutamate is a major neurotransmitter in the mammalian nervous system and plays an important role in many physiological functions including brain development and learning (Malenka and Nicoll 1993). On the other hand, glutamate is known to be a potent neurotoxin when present in excess at synapses (Plaitakis and Shashidaran 2000). Glutamate excitotoxicity contributes to neuronal degeneration in acute conditions such as stroke, epilepsy, trauma, hypoxia and hypoglycaemia and chronic neurodegenerative diseases such as PD but also Alzheimer's and Huntington's disease and amyotrophic lateral sclerosis (Lipton and Rosenberg 1994). There is general agreement that glutamate action is Ca2+dependent and the N-methyl-D-aspartate (NMDA) subtype of glutamate receptors plays a key role in

mediating glutamate toxicity (Sattler and Tymiansky 2000). Ca<sup>2+</sup> loading exceeding the capacity of Ca<sup>2+</sup> regulating mechanisms could activate several cell death-related genes and pathways (Said et al. 2000). These include calcium-dependent activation of nucleases, lipases, proteases and neuronal nitric oxide synthase, thus increasing oxidative stress (Doble 1999).

#### Ginsenosides reduce glutamate excitotoxicity in vitro

Ginsenosides Rb1 and Rg3 protected cultured rat cortical cells from glutamate-induced neurodegeneration (Kim et al. 1998). In our studies on glutamate excitotoxicity (Radad et al. 2004b), primary dopaminergic neurons from embryonic mouse mesencephala were exposed to a neurotoxic glutamate concentration and protective effects of ginsenosides Rb1 and Rg1 on survival and neuritic growth of the cells were tested. Excessive glutamate promoted the release of lactate dehydrogenase, propidium iodide uptake by the cells and increased the number of nuclei with condensed and fragmented chromatin as apoptotic characteristics. Moreover, glutamate extensively reduced tyrosine hydroxylase immunopositive cells and adversely affected the appearance of their neuronal processes. The toxic effect of glutamate was primarily caused by over-activation of the N-methyl-d-aspartate (NMDA) receptor as treatment of cultured cells with (+)MK 801, a NMDA receptor antagonist, nearly abolished the dopaminergic cell loss and LDH release induced by glutamate. Pre-treating and post-treating with ginsenosides Rb1 and Rg1 to glutamate exposure significantly increased the numbers and lengths of neurites of surviving dopaminergic cells. Thus ginsenosides Rb1 and Rg1 appear to exert partial neurotrophic and neuroprotective functions against glutamate in cell culture (Radad et al. 2004b).

# Ginsenosides as neuroprotectants

Reflecting the "panacea" status of ginseng a multitude of possible effects may be held responsible for the neuroprotectant effects of ginsenosides. The large variety of ginsenosides, their complex composition, depending on the particular variety of the ginseng plant and the effect of the processing steps to get a final product as white ginseng, red or even black ginseng and not to forget metabolic conversions, make it difficult to focus on a single pharmacological mechanism.

The prominent ginsenosides Rb1 and Rg1 have been most tested, but currently metabolites also gain importance.

Ginsenosides promote cell proliferation and enhance the survival rate of new-born cells. Ginsenosides Rb1 and Rg1 elevated NGF mRNA expression in rat brain (Salim et al. 1997). Ginsenosides have neurotrophic effects, as they reversed the neurotoxic effects of MPP+ through elevation of mRNA expression of NGF (O'Hara et al. 1998). Nonneuronal effects of ginsenosides as stimulating endothelial growth and thus promoting angiogenesis could contribute to neuroregeneration (Huang et al. 2005).

Preserving neuronal function by ginsenosides, as in improvement of learning and memory and counteracting stress and depression, appears to be by modulating neuronal, e.g., hippocampal activity. Neuroprotective effects in ischemia models could reflect energetic sparing by preserving ATP stores. A rise of free radicals due to environmental toxins and mitochondrial dysfunction can be counteracted by different ginsenosides, given their different potencies as antioxidants or free radical scavengers. In vitro the orders of antioxidative ability are Rc > Rb1 and Re > Rd > R1 > Rg1 > Rb3 > Rh1, respectively (Liu et al. 2003).

Aging causes suppression of the antioxidative defense systems and accumulation of lipid peroxidation products. In early senescent mice ginsenoside-Rd attenuates the oxidative damage, which may be related to the intervention of the GSH/GSSG redox status (Yokozawa et al, 2004). Membrane stabilizing effects, such as physicochemical properties adding to cell survival, could be relevant for ginsenoside action. The increment found with ginsenoside Rg1 has been viewed as part of Rg1's antiaging action (Li and Zhang 1997). Estrogen actions of ginsenosides, so far have not been explicitly correlated to brain and neuronal function, but mainly to anti-tumor action (Chan et al. 2002).

Most effects of ginsenosides are related to their NMDA-receptor actions, counteracting excitotoxicity by glutamate. In particular ginsenoside Rg3 inhibits both N-methyl-D-aspartate (NMDA) and non-NMDA glutamate receptors (Kim et al. 2002, Kim and Rhim 2004) which could be relevant to many neurological disorders particularly brain ischemia, trauma, stroke, and seizures (Choi and Rothman 1990). Inhibition of NMDA and non-NMDA receptors by ginsenosides resulted in a reduction of Ca<sup>2+</sup> over-influx into neurons and thus protected cells from neurodegenerative processes evoked by Ca<sup>2+</sup> overload (Liao et al. 2002).

Counteracting neuroinflammatory processes could well be another potential for specific ginsenosides.

Anti-inflammatory activity of ginsenoside Rb1, and its metabolite compound K, produced by intestinal bacteria, on lipopolysaccharide (LPS)-stimulated murine macrophages, were studied. Compound K potently inhibited the production of NO and prostaglandin E2, reduced the expression levels of the inducible NO synthase (iNOS) and COX-2 proteins, and prevented the activation of NF-kB (Park et al. 2005).

Antitapoptotic effects have been tested for ginsenosides. Ginseng attenuated MPP+-induced apoptosis as it decreased the intensity of MPP+-induced DNA laddering in PC12 cells and ginsenoside Rg1 had a protective effect against MPTP-induced apoptosis in the mouse substantia nigra. This anti-apoptotic effect of ginseng may be attributed to enhanced expression of Bcl-2 and Bcl-xl, reduced expression of bax and nitric oxide synthase, and inhibited activation of caspase-3 (Chen et al. 2002, Kim et al. 2003).

### **CONCLUSIONS**

Recent experimental evidence provides detailed indications of neuroprotective properties of ginsenosides in cell culture systems and animal studies. Considering the large number of structural analogues of ginsenosides, controversial effects and complex additive interactions have and had to be expected. The approach to use of ginsenosides to affect ongoing chronic processes in neurodegenerative and aging diseases as PD, Alzheimer disease and neuronal degeneration due to ischemic and neuroinflammatory events, is tempting, based on experimental data. A long medical history of these compounds and the relative lack of side effects make them additionally attractive. Yet, though such aspects maybe stimulating, it is clearly a long way from in vitro data to a proven neuroprotective potential in human disease. It will require validated data from the clinic and here particularly imaging techniques and long term follow-up, as to actually prove whether the postulated neuroprotective action of ginseng and/or its saponins have this desired effect in neurodegenerative disorders.

#### REFERENCES

- Antkiewicz-Michaluk L, Karolewicz B, Romanska I, Michaluk J, Bojarski AJ, Vetulani J (2003) 1-Methyl-1,2,3,4-tetrahydroisoquinoline protects against rotenoneinduced mortality and biochemical changes in rat brain. Eur J Pharm 466: 263–269.
- Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT (2000) Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 3: 1301–1306.
- Blumenthal M (2001) Asian ginseng: Potential therapeutic uses. Adv Nurse Pract 2: 26–28.
- Chen XC, Chen Y, Zhu YG, Fang F, Chen LM (2002) Protective effect of ginsenoside Rg1 against MPTP-induced apoptosis in mouse substantia nigra neurons. Acta Pharmacol Sin 23: 829–834.
- Chan RY, Chen WF, Dong A, Guo D, Wong MS (2002) Estrogen-like activity of ginsenoside Rg1 derived from Panax notoginseng. J Clin Endocrinol Metab 87: 3691–3695.
- Choi DW, Rothman SM (1990) The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death. Annu Rev Neurosci 13: 171–182.
- Chun CX, Gui ZY, An ZL, Chun H, Ying C, Min CL, Fang F, Can ZY, Hui ZC (2003) Ginsenoside Rg1 attenuates dopamine-induced apoptosis in PC12 cells by suppressing oxidative stress. Eur J Pharmacol 473: 1–7.
- Doble A (1999) The role of excitotoxicity in neurodegenerative disease: Implication for therapy. Pharmacol Ther 81: 163–221.
- Gerlach M, Double KI, Youdim MBH, Riederer P (2000) Strategies for protection of dopaminergic neurons against neurotoxicity. Neurotox Res 2: 99–114.
- Huang YC, Chen CT, Chen SC, Lai PH, Liang HC, Chang Y, Yu LC, Sung HW (2005) A natural compound (ginsenoside Re) isolated from Panax ginseng as a novel angiogenic agent for tissue regeneration. Pharm Res 22: 636–646.
- Kennedy DO, Scholey AB (2003) Ginseng: potential for the enhancement of cognitive performance and mood. Pharmacol Biochem Behav 75: 687–700.
- Kim YC, Kim SR, Markelonis GJ, Oh TH (1998) Ginsenosides Rb1 and Rg3 protect cultured rat cortical cells from glutamate-induced neurodegeneration. J Neurosci Res 4: 426–432.
- Kim S, Ahn K, Oh TH, Nah SY, Rhim H. (2002) Inhibitory effect of ginsenosides on NMDA receptor-mediated signals in rat hippocampal neurons. Biochem Biophys Res Commun 296: 247–254.

- Kim EH, Jang MH, Shin MC, Shin MS, Kim CJ (2003) Protective effect of aqueous extract of Ginseng radix against 1-methyl-4-phenylpyridinium-induced apoptosis in PC12 cells. Biol Pharm Bull 26: 1668–1673.
- Kim S, Rhim H (2004) Ginsenosides inhibit NMDA receptor-mediated epileptic discharges in cultured hippocampal neurons. Arch Pharm Res 27: 524–530.
- Kim JH, Lee JH, Yoon IS, Jeong SM, Lee BH, Lee JH, Lee SM, Nah SY (2006) Ginseng saponins attenuate neurotoxicity on 3-nitropropionic acid induced striatal degeneration in rats. In: Advances in Ginseng Research (Oh S, Choi KT, eds). The Korean Society of Ginseng, Geumsan Korea, p. 122–147.
- Leung KW, Yung KKI, Mak NK, Chan YS, Fan DTP, Wong RNS (2006) Neuroprotective effects of ginsenoside Rg1 in dopaminergic neurons against rotenone toxicity. In: Advances in Ginseng Research (Oh S, Choi KT, eds). The Korean Society of Ginseng, Geumsan Korea, p. 727.
- Li JQ, Zhang JT (1997) Effects of age and ginsenoside RG1 on membrane fluidity of cortical cells in rats. Yao Xue Xue Bao 32: 23–27
- Liao B, Newmark H, Zhou R (2002) Neuroprotective effects of ginseng total saponin and ginsenosides Rb1 and Rg1 on spinal cord neurons in vitro. Exp Neurol 173: 224–234.
- Lim JH, Wen TC, Matsuda S, Tanaka J, Maeda N, Peng H, Aburaya J, Ishihara K, Sakanaka M (1997) Protection of ischaemic hippocampal neurons by ginsenosides Rb1, a main ingredient of ginseng root. Neurosci Res 28: 191–200.
- Lipton SA, Rosenberg PA (1994) Excitatory amino acids as a final common pathway for neurologic disorders. Engl J Med 330: 613–622.
- Liu ZQ, Luo XY, Liu GZ, Chen YP, Wang ZC, Sun YX (2003) In vitro study of the relationship between the structure of ginsenoside and its antioxidative or prooxidative activity in free radical induced hemolysis of human erythrocytes. J Agric Food Chem 51: 2555–2558.
- Liu TT (2006) Role of ginseng in neurodegenerative disorders. In: The chemistry and Metabolism and Biological Activities of Ginseng. (Zhang JT, Chui DH, Chen CF, eds). Chemical Industry Press, Beijing, China, p. 226–240.
- Malenka RC, Nicoll RA (1993) NMDA-receptor-dependent synaptic plasticity: Multiple forms and mechanism. Trends Neurosci 16: 521–527.
- Moon JH, Lee YC, Lee JH, Song WH, Kang DO, Cho YK (2006) Protective effects of Panax ginseng against apoptotic death induces by polychlorinated biphenyls in

- human neuronal cells. In: Advances in Ginseng Research (Oh S, Choi KT, eds). The Korean Society of Ginseng, Geumsan Korea, p. 265–284.
- Noverino E, Amato M, Izzo AA (2000) The aphrodisiac and adaptogenic properties of ginseng. Fitoterapia 71: 1-5.
- O'Hara M, Kiefer D, Farrell K, Kemper K (1998) A review of 12 commonly used medicinal herbs. Arch Fam Med 7: 523-536.
- Park EK, Shin YW, Lee HU, Kim SS, Lee YC, Lee BY, Kim DH (2005) Inhibitory effect of ginsenoside Rb1 and compound K on NO and prostaglandin E2 biosyntheses of RAW264.7 Cells induced by lipopolysaccharide. Biol Pharm Bull 28: 652-656.
- Persson J, Bringlov E, Nilsson LG, Nyberg L (2004) The memory-enhancing effects of Ginseng and Ginkgo biloba in healthy volunteers. Psychopharmacology 172: 430-434.
- Plaitakis A, Shashidharan P (2000) Glutamate transport and metabolism in dopaminergic neurons of substantia nigra: Implications for the pathogenesis of Parkinson's disease. J Neurol 247: 1125.
- Radad K, Gille G, Moldzio R, Saito H Ishige K, Rausch WD (2004a) Ginsenosides Rb1 and Rg1 effects on survival and neurite growth of MPP+ -affected mesencephalic cells. J Neural Transm 111: 37-45.
- Radad K, Gille G, Moldzio R, Saito H, Rausch WD (2004b) Ginsenosides Rb1 and Rg1 effects on mesencephalic dopaminergic cells stressed with glutamate. Brain Res 1021: 41–53.
- Radad K, Gille G, Rausch WD (2005) Short review on dopamine agonists: Insight into clinical and research studies relevant to Parkinson's disease. Pharmacol Rep 57: 701-712
- Said SI, Pakbaz H, Berisha HI, Raza S (2000) NMDA receptor activation: Critical role in oxidant tissue injury. Free Radic Bio Med 28: 1300-1302.

- Salim KN, McEven BS, Choa HM (1997) Ginsenoside Rb1 regulates ChAT, NGF and trkA mRNA expression in the rat brain. Brain Res Mol Brain Res 47: 177-182.
- Sattler R, Tymiansky M (2000) Molecular mechanism of calcium dependent excitotoxicity. J Mol Med 78: 3-13.
- Shen L, Zhang J (2003) Ginsenoside Rg1 increases ischemia-induced cell proliferation and survival in the dentate gyrus of adult gerbils. Neurosci Lett 344: 1-4.
- Terasawa K, Shimada Y, Kita T (1997) Choto-san in the treatment of vascular dementia: A double blind, placebocontrolled study. Phytomedicine 4: 15-22.
- Tsang D, Yeung HW, Tso WW, Peck H (1985) Ginseng saponins: influence on neurotransmitter uptake in rat brain synaptosomes. Planta Med 3: 221-224.
- Tyler VE (1993) The Honest Herbal-A Sensible Guide to the Use of Herbs and Related Remedies (Third ed.). The Haworth Press, New York.
- Van Kampen J, Robertson H, Hagg T, Drobitch R (2003) Neuroprotective actions of the ginseng extract G115 in two rodent models of Parkinson's disease. Exp Neurol 184: 21-29.
- Wen TC, Yoshimura H, Matsuda S, Lim JH, Sakanaka M (1996) Ginseng root prevents learning disability and neuronal loss in gerbils with 5-minute forebrain ischaemia. Acta Neuropathol 91: 15-22.
- Yamaguchi Y, Higashi M, Kobayashi H (1996) Effects of ginsenosides on impaired performance caused by scopolamine in rats. Eur J Pharmacol 312: 149-151.
- Yokosawa T, Satoh A, Cho FJ (2004) Ginsenoside-Rd attenuates oxidative damage related to aging in senecenceaccelerated mice. J Phar Pharmacol 56: 107–113.
- Yun TK (2001) Brief introduction of Panax ginseng C.A. Meyer. J Korean Med Sci 16: 53-55.
- Zhang JT (2006) The Chemistry and Metabolism and Biological Activities of Ginseng (Zhang JT, Chui DH, Chen CF, eds). Chemical Industry Press, Beijing, China.

Received 9 September 2006, accepted 9 November 2006